Skip to main content
Premium Trial:

Request an Annual Quote

The Drying Pipeline

Both AstraZeneca and Novartis announced that drugs they had for depression and hypertension that were in the late stages of development have failed, reports Bloomberg, adding that AstraZeneca's drugs turned out to be disappointing while Novartis's tests on Tekturna were halted due to safety concerns. Further, Sanofi's multiple sclerosis drug, Aubagio, has not performed better than an older therapy.

"The bad results emerged at the same time, but Novartis has been at the top of the leader board for drug launches over the past decade, while AstraZeneca lies more toward the bottom," Gbola Amusa, an analyst at UBS AG, tells Bloomberg. And except for an injectable MS drug at Safnoi "and perhaps one or two other drugs, there isn't a lot else that's cause for excitement in that pipeline."

The Scan

Missed Early Cases

A retrospective analysis of blood samples suggests early SARS-CoV-2 infections may have been missed in the US, the New York Times reports.

Limited Journal Editor Diversity

A survey finds low diversity among scientific and medical journal editors, according to The Scientist.

How Much of a Threat?

Science writes that need for a provision aimed at shoring up genomic data security within a new US bill is being questioned.

PNAS Papers on Historic Helicobacter Spread, Brain Development, C. difficile RNAs

In PNAS this week: Helicobacter genetic diversity gives insight into human migrations, gene expression patterns of brain development, and more.